- methods and metrics
- costing methods
- health outcomes
- evidence synthesis
- test performance
- value of information
- models and tools
- mathematical models
- state-transition
- dynamic transmission
- microsimulation
- calibration/validation
- dynamic simulation
- chronic disease/risk
- global governance
- science/technology
- sub-saharan africa
- europe
- asia & pacific
Resources Repository
-
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Microsimulation | Mathematical Models | Dynamic Transmission | State-Transition | Health Outcomes | Science/Technology | Asia & Pacific | Sub-Saharan Africa | Global Governance | Infectious Diseases | Economics/Finance | Health/Medicine | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Mathematical Models | Costing Methods | Health Outcomes | Science/Technology | Asia & Pacific | Sub-Saharan Africa | Global Governance | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Economics/Finance | Health/Medicine | Middle East & North Africa -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Costing Methods | Health Outcomes | Science/Technology | Asia & Pacific | Sub-Saharan Africa | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Microsimulation | Mathematical Models | Calibration/Validation | Science/Technology | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Evidence Synthesis | Value of Information | Science/Technology | Europe | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | North America -
Resource PortalPublication, Teaching Resource 2017Immunization Financing: A Resource Guide
This resource guide compiles 26 briefs on topics related to the cost and financing of …
This resource guide compiles 26 briefs on topics related to the cost and financing of national immunization programs in low- and middle-income countries. The guide provides information and analysis to help advocates, policymakers, and program managers assess different financing options, approaches to strategic purchasing, and strategies for policy change, incorporating recent country experience in these areas. The guide is an update to the Immunization Financing Toolkit: A Resource for Policy-Makers and Program Managers, published by…
Costing Methods | Science/Technology | Asia & Pacific | Sub-Saharan Africa | Global Governance | Priority Setting/Ethics | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Middle East & North Africa | Latin America & Caribbean | College | Graduate | Doctoral | Professional | Decision Making/Leadership | Policy Translation | Quantitative Literacy -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Microsimulation | Calibration/Validation | Science/Technology | Sub-Saharan Africa | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2008Health and Economic Impact of HPV 16 and 18 Vaccination and Cervical Cancer Screening in India
As cervical cancer is a leading cause of cancer death among women in low-income countries, …
As cervical cancer is a leading cause of cancer death among women in low-income countries, with approximately 25% of cases worldwide occurring in India, these authors estimated the potential health and economic impact of different cervical cancer prevention strategies in India. After empirically calibrating a cervical cancer model to country-specific epidemiologic data, they projected cancer incidence, life expectancy, and lifetime costs (I$2005), and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of…
Microsimulation | Calibration/Validation | Science/Technology | Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Clinical Care | Economics/Finance | Health/Medicine -
Resource PackWeb Portal, Teaching Resource 2023Resource Pack: Cost-Effectiveness of Screening and Treatment for Hypertension
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, …
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, and cost-effectiveness analysis. This resource pack provides examples of decision analyses and cost-effectiveness analyses for the management and treatment of hypertension, with a predominant focus on the U.S. Analyses are included that predate the 2017 American College of Cardiology/American Heart Association Clinical Practice Guidelines, along with more recent examples that followed release of the guidelines. Resources are also included that…
Test Performance | Science/Technology | Europe | Chronic Disease/Risk | Preferences/Values | Decision Analysis | Cost-Effectiveness Analysis | Clinical Care | Economics/Finance | Health/Medicine | North America | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy